Pseudocholinesterase Phenotype
Test Mnemonic
PCHEP
CPT Codes
- 82480 - QTY (1)
- 82638 - QTY (1)
Aliases
- Dibucaine Number
- Pseudocholinesterase, Dibucaine Inhibition
Includes
- Pseudocholinesterase
- Dibucaine Number
Performing Laboratory
ARUP
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Refrigerated | Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Plasma | EDTA (Lavender) | Refrigerated | Separate plasma from cells ASAP or within 2 hours of collection | |
| 1 mL | Plasma | Sodium or Lithium heparin (Green) | Refrigerated | Separate plasma from cells ASAP or within 2 hours of collection |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.25 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 4 hours |
| Refrigerated | 1 week |
| Frozen | 3 months |
Days Performed
Mon - Fri
Turnaround Time
2 - 6 days
Methodology
| Name | Description |
|---|---|
| Enzymatic |
Reference Range
| Pseudocholinesterase, Total | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Years | 99 Years | Normal | 2900-7100 | U/L |
Special Info
Specimen must be drawn prior to surgery or at least > 2 days post surgery; Do not draw in recovery room; Sodium citrate (light blue) or oxalate/fluoride (gray) tubes are unacceptable. Whole blood is not acceptable. This test is New York DOH approved. Specimens should be collected 48 hours after the administration of succinylcholine.
Clinical Info
Screening test for patients who are hypersensitive to succinylcholine due to atypical pseudocholinesterase. Patients with acute or chronic liver disease, organophosphate poisoning, chronic renal disease, in late stages of pregnancy, or on estrogen therapy may have markedly decreased PChE activities.